Home > Back to Publisher > Report Information

Commercial Insight: Antihormonal Cancer Therapies

Datamonitor
July 16, 2009
108 Pages - SKU: DFMN2391540

Abstract Table of Contents Related Reports

Introduction

Antihormonal cancer therapies are a class of drugs used predominantly in the treatment of breast cancer and prostate cancer. The high incidence of these tumor types translates into a significant commercial potential for drug developers. Collectively, the antihormonal therapy cancer brands generated sales of about $6.9 billion in the seven major pharmaceutical markets in 2008.

Scope

In-depth analysis of the current and future antihormonal therapies market across the US, 5EU and Japan, plus a rest of world snapshot
Antihormonal therapy sales forecasts for brands and generics from 2008 to 2018
Assessment of the leading cancer brands and drug classes to identify key success factors within this sector
Evaluation of the strategies of leading players in the antihormonals market

Highlights

The antihormonals market was worth $6.9 billion in 2008 across the seven major pharmaceutical markets. Its growth within the next decade, at a marginal CAGR of 0.1%, will be predominantly limited by patent expiries of leading brands.

In 2008, Arimidex (anastrozole; AstraZeneca), Lupron (leuprolide; Takeda/Abbott) and Casodex (bicalutamide; AstraZeneca) were the three leading antihormonal brands in terms of sales. These will remain the top three brands through to 2018, even though Arimidex and Casodex will lose around 40% of their brand value due to generic competition.

In a mature market, the importance of product lifecycle management is high. AstraZeneca was the key player in the market in 2008, with an antihormonals portfolio valued at over $3.4 billion. With successful lifecycle management and a considerable investment in marketing activities, AstraZeneca has built a strong brand presence for its products.

Reasons to Purchase

Quantify the performance of each of the marketed antihormonal therapy cancer brands in the seven major markets over the period 2008 to 2018
Acquire a detailed account of antihormonal therapy cancer brand dynamics and the events that drive and limit their market growth
Benchmark the antihormonal therapy cancer brands against generics and rest of class and align their 7MM performance with a rest of world snapshot

Please note: this is delivered as a Zip file.

ABOUT DATAMONITOR HEALTHCARE: About the Oncology pharmaceutical analysis team
CHAPTER 1 EXECUTIVE SUMMARY: Strategic scoping and focus; Datamonitor insight into the antihormonal cancer therapies market; Related reports; Upcoming related reports
CHAPTER 2 MARKET DEFINITION: Definition of the cancer market; Antihormonal therapies by ATC class; L2A3 - Luteinizing hormone-releasing hormone agonists; L2B1 - Anti-estrogens; L2B2 - Anti-androgens; L2B3 - Aromatase inhibitors; L2B9 - Other hormone antagonists
CHAPTER 3 MARKET OVERVIEW: Seven major markets; Current and future market overview; The antihormonal therapies market will grow marginally in the forecast period; Patent expiries of leading antihormonal brands are set to occur within the next 5 years; The US will suffer the greatest impact of generic erosion, losing about 25% of its value in the forecast period; The aromatase inhibitors will continue to be the leading drug class in 2018; The current leading antihormonal brands will suffer generic sales erosion but will maintain a high level of sales; The antihormonal therapies market will grow from $6.9 billion in 2008 to $7.0 billion in 2018 across the seven major pharmaceutical markets; Opportunities and threats; Opportunities; Threats; US; Current and future market assessment; The US antihormonals market will suffer the greatest impact of generic sales erosion; The value of the antihormonals market will decrease from $2.7 billion in 2008 to $2.0 billion in 2018 in the US; Opportunities and threats; Opportunities; Threats; Japan; Current and future market assessment; The antihormonal therapies market in Japan is forecast to grow over the forecast period; The antihormonals market will grow from $1.6 billion in 2008 to $1.8 billion in 2018 in Japan; Opportunities and threats; Opportunities; Threats; Five major European markets (5EU); Current and future market assessment; The antihormonal therapies market in the five European countries will show marginal growth; The antihormonal therapies market will grow from $2.6 billion in 2008 to $3.1 billion in 2018 in the five major European markets; Opportunities and threats; Opportunities; Threats; France; Current and future market assessment; The antihormonal therapies market will grow from $682m in 2008 to $810m in 2018 in France; Germany; Current and future market assessment; The antihormonals therapies market will grow from $754m in 2008 to $947m in 2018 in Germany; Italy; Current and future market assessment; The antihormonal therapies market will grow from $376m in 2008 to $421m in 2018 in Italy; Spain; Current and future market assessment; The antihormonal therapies market will grow from $395m in 2008 to $470m in 2018 in Spain; UK; Current and future market assessment; The antihormonal therapies market will grow from $430m in 2008 to $479m in 2018 in the UK; Rest of the world snapshot; Current market assessment; Rest of the world sales represent 23% of the global antihormonals market; Opportunities and threats; Opportunities; Threats
CHAPTER 4 BRAND DYNAMICS: Overview of competitive landscape; Arimidex, Lupron and Casodex will remain the top 3 antihormonal brands in 10 years' time; Drivers of brand choice; Efficacy and toxicity are the most important drivers of brand choice; Trends in marketing strategies; Marketing strategy for leading brands; Patient information and support programs; Direct-to-Consumer advertising; Arimidex (anastrozole; AstraZeneca); Drug profile; Product positioning; SWOT analysis; Brand forecast to 2018; Arimidex set to maintain its blockbuster status despite patent expiry; Lupron (leuprolide; Takeda/Abbott); Drug profile; Product positioning; SWOT analysis; Brand forecast to 2018; Lupron will be the top selling antihormonal therapy in 2018, with sales in excess of $1 billion; Casodex (bicalutamide; AstraZeneca); Drug profile; Product positioning; SWOT analysis; Brand forecast to 2018; Patent expiries set to hamper sales of this class-leading brand
CHAPTER 5 KEY DEVELOPERS: Strategic overview; Trends in corporate strategy; Strategic lifecycle management is essential in the antihormonals market; Commercialization partnerships are common for smaller players; AstraZeneca; Corporate strategy; Oncology antihormonals portfolio assessment; Takeda; Corporate strategy; Oncology antihormonals portfolio assessment; Portfolio assessment of other leading companies
CHAPTER 6 CASE STUDY: Portfolio management: the example of AstraZeneca; A first-to-market status is a good start...; ...but strategic portfolio management is essential to maintain shareholder value; AstraZeneca's ambitious plans for Arimidex paid off...; ...and the approval of Faslodex continued a strong investment in the breast cancer market; Expanding into the prostate cancer market strengthened AstraZeneca's portfolio value
BIBLIOGRAPHY: Datamonitor reports; Other

APPENDIX A - MARKET ASSUMPTIONS: New product launches; Patent expiries; Data definitions, limitations and assumptions; Standard units; Japanese market data; Rest of World; Derivation of sales forecasts and pricing trends; Forecast methodology

APPENDIX B: About Datamonitor; About Datamonitor Healthcare; About the Oncology analysis team; Disclaimer
List of Tables: Table 1: Definition of the cancer market, 2009; Table 2: Sales and growth of antihormonal therapy drug classes in the seven major markets, 2008-2018; Table 3: Key events impacting the antihormonal therapies market, 2008-2018; Table 4: Antihormonal therapies sales forecasts in the seven major markets ($m), 2008-2018; Table 5: Summary of opportunities and threats to impact the antihormonals market across the seven major markets, 2009; Table 6: Sales and growth of antihormonal therapy drug classes in the US, 2008-2018; Table 7: Top 5 branded antihormonals in the US in 2008 and 2018; Table 8: Antihormonal therapy sales forecasts in the US ($m), 2008-2018; Table 9: Summary of opportunities and threats to impact the antihormonal market in the US, 2009-2018; Table 10: Sales and growth of antihormonal therapy drug classes in Japan, 2008-2018; Table 11: Top 5 branded antihormonals in Japan in 2008 and 2018; Table 12: Antihormonal therapy sales forecasts in Japan ($m), 2008-2018; Table 13: Summary of opportunities and threats to impact the antihormonals market in Japan, 2009-2018; Table 14: Sales and growth of antihormonal therapy drug classes in the five major European markets, 2008-2018; Table 15: Top 5 branded antihormonals in the five major European markets in 2008 and 2018; Table 16: Antihormonal therapy sales forecasts in the five major European markets ($m), 2008-2018; Table 17: Summary of opportunities and threats to impact the antihormonals market in the five major European markets, 2009; Table 18: Top 5 branded antihormonals in France in 2008 and 2018; Table 19: Antihormonal therapy sales forecasts in France ($m), 2008-2018; Table 20: Top 5 branded antihormonals in Germany in 2008 and 2018; Table 21: Antihormonal therapy sales forecasts in Germany ($m), 2008-2018; Table 22: Top 5 branded antihormonals in Italy in 2008 and 2018; Table 23: Antihormonal therapy sales forecasts in Italy ($m), 2008-2018; Table 24: Top 5 branded antihormonals in Spain in 2008 and 2018; Table 25: Antihormonal therapy sales forecasts in Spain ($m), 2008-2018; Table 26: Top 5 branded antihormonals in the UK in 2008 and 2018; Table 27: Antihormonal therapy sales forecasts in the UK ($m), 2008-2018; Table 28: Comparison of antihormonal drug class sales ($m) in the seven major markets and rest of the world, 2008; Table 29: Leading branded antihormonal therapy drug sales in the seven major markets ($m), 2008-2018; Table 30: Marketing strategies employed by companies behind the top 3 antihormonal brands, 2009; Table 31: Arimidex (anastrozole) - drug profile, 2009; Table 32: Impacting factors on the revenues of Arimidex, 2008-2018; Table 33: Lupron (leuprolide) - drug profile, 2009; Table 34: Impacting factors on the revenues of Lupron, 2008-2018; Table 35: Casodex (bicalutamide) - drug profile, 2009; Table 36: Impacting factors on the revenues of Casodex, 2008-2018; Table 37: Leading companies in the antihormonals market in the seven major pharmaceutical markets, 2008-2018; Table 38: Assessment of AstraZeneca's cancer antihormonals portfolio, 2009; Table 39: Assessment of Takeda's cancer antihormonals portfolio, 2009; Table 40: Assessment of Novartis's cancer antihormonals portfolio, 2009; Table 41: Assessment of Pfizer's cancer antihormonals portfolio, 2009; Table 42: Assessment of Sanofi-Aventis's cancer antihormonals portfolio, 2009; Table 43: Regional launch dates for new antihormonals in the seven major markets, 2008-2018; Table 44: Patent expiry dates for the approved antihormonals in the seven major pharmaceutical markets, 2008-2018
List of Figures: Figure 1: Comparison of brand versus generic value of antihormonal therapies in 2008 and 2018 in the seven major pharmaceutical markets; Figure 2: Antihormonal therapy sales ($m) by country, 2008-2018; Figure 3: Antihormonal therapy sales ($m) by drug class in the seven major markets, 2008-2018; Figure 4: Performance of leading antihormonal therapy brands in the seven major markets, 2008 versus 2018; Figure 5: Antihormonal therapy sales ($m) in the US, 2008-2018; Figure 6: Antihormonal therapy sales ($m) in Japan, 2008-2018; Figure 7: Antihormonal therapy sales ($m) in the five major European markets, 2008-2018; Figure 8: Antihormonal therapy sales ($m) in France, 2008-2018; Figure 9: Antihormonal therapy sales ($m) in Germany, 2008-2018; Figure 10: Antihormonal therapy sales ($m) in Italy, 2008-2018; Figure 11: Antihormonal therapy sales ($m) in Spain, 2008-2018; Figure 12: Antihormonal therapy sales ($m) in the UK, 2008-2018; Figure 13: Rest of the world versus seven major market sales split in the antihormonal therapies market ($m), 2008; Figure 14: Drivers of brand choice for antihormonal cancer therapy, 2009; Figure 15: Example of Arimidex patient information and support programs; Figure 16: Femara free trial program; Figure 17: Frequency of cancer-related DTC advertising, January 2003-June 2006; Figure 18: Arimidex SWOT analysis, 2009; Figure 19: Arimidex forecast sales ($m) by country in the seven major markets, 2008-2018; Figure 20: Lupron SWOT analysis, 2009; Figure 21: Lupron forecast sales ($m) by country in the seven major markets, 2008-2018; Figure 22: Casodex SWOT analysis, 2009; Figure 23: Casodex forecast sales ($m) by country in the seven major markets, 2008-2018

Commercial Insight: Antihormonal Cancer Therapies

Share this report

Other tasks

Research Assistance

Related Markets

Oncology/Hematology Reports

Free Alert Me service